IMV News and Press, IMV Inc. From 08/11/22

IMV Inc. (IMV) Q2 2022 Earnings Conference Call August 11, 2022 08:00 ET Company Participants Brittany Davison - Senior Vice President of Finance Andrew Hall - Chief Executive Officer Jeremy Graff - Chief Medical Officer Conference Call Participants ...

IMV press release ( NASDAQ: IMV ): Q2 GAAP EPS of -$0.12. Revenue of $0.03M (-25.0% Y/Y). On June 30, 2022, the Company had cash and cash equivalents of $31.1M and working capital of $27.7M, compared with $38.6M and $37.1M, respectively at December 31, 2021. Based ...

Patient recruitment in the Phase 2B VITALIZE DLBCL trial of MVP-S plus Keytruda continues to track well, with first results expected in Q3 2022. Matthew J. Matasar, MD from Memorial Sloan Kettering Cancer Center, has joined VITALIZE as lead principal investigator of the study. ...

IMV Inc. (“ IMV ” or the “ Company ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that it pla...

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference cal...

IMV ( NASDAQ: IMV ) received a letter from Nasdaq for not meeting the minimum bid price of $1.00 per share required for continued listing. Company may be eligible for an additional 180 calendar days to regain compliance. For further details see: IMV receives...

IMV Inc. (“ IMV ” or the “ Company ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ™ platform to treat solid and hematologic cancers, today announced that on J...

IMV achieves predetermined milestone to access the remaining $US10 Million under its Debt Facility with Horizon Phase 2b AVALON trial in platinum-resistant ovarian cancer open for enrollment IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a ...

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be participating...

The following slide deck was published by IMV Inc. in conjunction with their 2022 Q1 earnings call. For further details see: IMV Inc. 2022 Q1 - Results - Earnings Call Presentation